Posterior Reversible Encephalopathy Syndrome in Patients with Coronavirus Disease 2019: Two Cases and A Review of The Literature

https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105212Get rights and content

Highlights

  • Posterior reversible encephalopathy syndrome may be associated with coronavirus disease.

  • Risk factors may include modest blood pressure fluctuations and anakinra.

  • All reported patients had clinical improvement.

Abstract

Introduction

Encephalopathy is a common complication of coronavirus disease 2019. Although the encephalopathy is idiopathic in many cases, there are several published reports of patients with posterior reversible encephalopathy syndrome in the setting of coronavirus disease 2019.

Objective

To describe the diverse presentations, risk factors, and outcomes of posterior reversible encephalopathy syndrome in patients with coronavirus disease 2019.

Methods

We assessed patients with coronavirus disease 2019 and a diagnosis of posterior reversible encephalopathy syndrome at our institution from April 1 to June 24, 2020. We performed a literature search to capture all known published cases of posterior reversible encephalopathy syndrome in patients with coronavirus disease 2019.

Results

There were 2 cases of posterior reversible encephalopathy syndrome in the setting of coronavirus 2019 at our institution during a 3-month period. One patient was treated with anakinra, an interleukin-1 inhibitor that may disrupt endothelial function. The second patient had an underlying human immunodeficiency virus infection. We found 13 total cases in our literature search, which reported modest blood pressure fluctuations and a range of risk factors for posterior reversible encephalopathy syndrome. One patient was treated with tocilizumab, an interleukin-6 inhibitor that may have effects on endothelial function. All patients had an improvement in their neurological symptoms. Interval imaging, when available, showed radiographic improvement of brain lesions.

Conclusions

Risk factors for posterior reversible encephalopathy syndrome in patients with coronavirus disease 2019 may include underlying infection or immunomodulatory agents with endothelial effects in conjunction with modest blood pressure fluctuations. We found that the neurological prognosis for posterior reversible encephalopathy syndrome in the setting of coronavirus disease 2019 infection is favorable. Recognition of posterior reversible encephalopathy syndrome in this patient population is critical for prognostication and initiation of treatment, which may include cessation of potential offending agents and tight blood pressure control.

Key Words

PRES
COVID-19
Immunosuppression

Cited by (0)

1

Contributed equally to this manuscript.

2

Additional Authors: Pria Anand, M.D. Work phone: (240) 888-2297, K.H. Vincent Lau, M.D. Work phone: (617) 638-8456, David Chung, M.D., Ph.D., Work phone: (617) 638-8456, Deepti Virmani, M.D. Work phone: (617) 638-8456, Anna Cervantes-Arslanian, M.D. Work phone: (617) 638-8456, Asim Z. Mian, M.D. Work phone: (617) 494-3899, Study Departments: Department of Neurology, Boston University School of Medicine; Department of Radiology, Boston University School of Medicine Institution: Boston Medical Center

View Abstract